SCHEMBL17455951

SCHEMBL17455951

Cn1cc(S(=O)(=O)N2CCC(Oc3c(C#N)cccc3-c3ccncc3)C2)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM1 P11229 1/20 0.41
▸ CCNA2 P20248 5/20 0.38
▸ CDK2 P24941 5/20 0.38
▸ HCRTR1 O43613 2/20 0.38
▸ HCRTR2 O43614 2/20 0.38
▸ CCNK O75909 1/20 0.35
▸ CDK12 Q9NYV4 1/20 0.35
▸ HTR1A P08908 3/20 0.34
▸ HTR7 P34969 3/20 0.34
▸ PIK3CD O00329 2/20 0.34
▸ TRPV4 Q9HBA0 1/20 0.34
▸ KDM1A O60341 1/20 0.34
▸ IKBKB O14920 1/20 0.34
▸ CHUK O15111 1/20 0.34
▸ UCHL1 P09936 1/20 0.34
▸ MCHR1 Q99705 1/20 0.34
▸ DRD2 P14416 1/20 0.34
▸ HTR2A P28223 1/20 0.34
▸ SCN3A Q9NY46 1/20 0.33
▸ RORC P51449 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17456057 0.84 IKBKB (0.43) HCRTR1HCRTR2PIK3CDTRPV4IKBKB
SCHEMBL17455970 0.77 CHRM1 (0.43) CHRM1HTR1AHTR7IKBKBCHUK
SCHEMBL17456027 0.76 CHRM1 (0.46) CHRM1CCNA2CDK2PIK3CD
SCHEMBL17456023 0.76 CHRM1 (0.42) CHRM1HTR1AHTR7IKBKBCHUK
SCHEMBL17455945 0.76 CHRM1 (0.43) CHRM1CCNA2CDK2HTR1AHTR7
SCHEMBL17455929 0.73 CHRM1 (0.40) CHRM1CCNA2CDK2HTR1AHTR7
SCHEMBL15549863 0.69 FPR2 (0.61) CCNA2CDK2CCNKCDK12RORC
SCHEMBL17455926 0.67 CHRM1 (0.38) CHRM1PIK3CDIKBKBCHUKMCHR1
SCHEMBL17456035 0.67 CHRM1 (0.38) CHRM1PIK3CDMCHR1
SCHEMBL26942298 0.65 CDK2 (0.48) CCNA2CDK2CCNKCDK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
EP-2982666-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024049-A1 HETEROCYCLIC COMPOUND PSEN1, PSEN2, BACE1 CHRM1 519/4885CCNA2 391/4885CDK2 440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback